SCHEMBL4273391

SCHEMBL4273391

CCCCOc1ccc2ccccc2n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.59
MEN1 O00255 1/20 0.59
KMT2A Q03164 1/20 0.59
TLR8 Q9NR97 4/20 0.58
GPBAR1 Q8TDU6 3/20 0.55
CYSLTR1 Q9Y271 2/20 0.55
CYSLTR2 Q9NS75 1/20 0.55
MCHR1 Q99705 1/20 0.46
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 3/20 0.46
GAA P10253 2/20 0.46
HPGD P15428 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
CYP1A2 P05177 2/20 0.46
ABCB11 O95342 1/20 0.46
LMNA P02545 1/20 0.46
CYP2D6 P10635 1/20 0.46
SCN1A P35498 1/20 0.46
OPRK1 P41145 1/20 0.46
KCNH2 Q12809 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL368050 0.95 TLR8 (0.59) MAPTMEN1KMT2ATLR8GPBAR1
SCHEMBL28276324 0.93 TLR8 (0.60) MAPTMEN1KMT2ATLR8GPBAR1
SCHEMBL16114537 0.93 TLR8 (0.60) MAPTMEN1KMT2ATLR8GPBAR1
SCHEMBL4269051 0.91 MEN1 (0.61) MAPTMEN1KMT2ATLR8GPBAR1
SCHEMBL30060467 0.91 MEN1 (0.61) MAPTMEN1KMT2ATLR8GPBAR1
SCHEMBL13196833 0.85 MAPT (0.55) MAPTMEN1KMT2ATLR8GPBAR1
SCHEMBL5735971 0.84 MEN1 (0.61) MAPTMEN1KMT2ATLR8GPBAR1
SCHEMBL9199234 0.84 MEN1 (0.61) MAPTMEN1KMT2ATLR8GPBAR1
SCHEMBL887723 0.83 MAPT (0.56) MAPTMEN1KMT2ATLR8CYSLTR1
SCHEMBL8067767 0.82 MEN1 (0.59) MAPTMEN1KMT2ATLR8GPBAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110981801-B Production process for preparing cinchocaine hydrochloride by one-pot method 山东诚汇双达药业有限公司 2023-02-24 CN claimed
CN-110606870-B Polypeptide for preventing and treating eimeria tenella and pharmaceutical composition containing polypeptide 广东省农业科学院动物卫生研究所 2021-02-19 CN claimed
CN-110606870-A Polypeptide for preventing and treating eimeria tenella and pharmaceutical composition containing polypeptide 广东省农业科学院动物卫生研究所 2019-12-24 CN claimed
CN-110312718-B Heterocyclene derivatives as pest control agents 拜耳公司 2023-02-28 CN disclosed
CN-110981801-B Production process for preparing cinchocaine hydrochloride by one-pot method 山东诚汇双达药业有限公司 2023-02-24 CN disclosed
CN-110981801-B Production process for preparing cinchocaine hydrochloride by one-pot method 山东诚汇双达药业有限公司 2023-02-24 CN disclosed
CN-114302953-A Bacillus strain and method for promoting plant growth 奥本大学 2022-04-08 CN disclosed
CN-113979941-A Method for purifying naphthoquine ester 瑞孚信江苏药业股份有限公司 2022-01-28 CN disclosed
CN-110606870-B Polypeptide for preventing and treating eimeria tenella and pharmaceutical composition containing polypeptide 广东省农业科学院动物卫生研究所 2021-02-19 CN disclosed
CN-110606870-A Polypeptide for preventing and treating eimeria tenella and pharmaceutical composition containing polypeptide 广东省农业科学院动物卫生研究所 2019-12-24 CN disclosed
US-20190315710-A1 Pd(II)-catalyzed Enantioselective Beta-Methylene C(sp3)–H Bond Activation THE SCRIPPS RESEARCH INSTITUTE 2019-10-17 US disclosed
CN-106306336-A Mildew inhibitor for pet feed 刘夕平 2017-01-11 CN disclosed
US-7605215-B2 Process for producing olefin copolymerization catalyst and process for producing olefin copolymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-10-20 US disclosed
US-20080227937-A1 Process for Producing Olefin Copolymerization Catalyst and Process for Producing Olefin Copolymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-09-18 US disclosed
WO-2005063777-A1 BENZYLPHOSPHATE AND SUBSTITUTED BENZYLPHOSPHATE PRODRUGS FOR THE TREATMENT OF PULMONARY INFLAMMATION CORUS PHARMA (US) 2005-07-14 WO disclosed
US-5405843-A Anticancer drug potentiators MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1995-04-11 US disclosed
EP-0363212-B1 Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components MITSUI TOATSU CHEMICALS (JP) 1995-01-04 EP disclosed
US-5204348-A Quinoline derivatives MITSUI TOATSU CHEMICALS INC. (JP) 1993-04-20 US disclosed
US-5112817-A Anticancer Drug Potentiators MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1992-05-12 US disclosed
EP-0363212-A2 Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components MITSUI TOATSU CHEMICALS, Inc. (JP) 1990-04-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190315710-A1 Pd(II)-catalyzed Enantioselective Beta-Methylene C(sp3)–H Bond Activation POLQ, AP3D1, AP3S1 MAPT 4416/4885MEN1 3613/4885KMT2A 787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.